Company / Working Capital
Anixa Biosciences Inc Working Capital History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$18.9M
FY2024
5-year range
$4.6M / $28.2M
FY2020-FY2024
Trend
-19.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $3M in FY2016 to $28M in FY2022.
Based on SEC 10-K filings.
$19M in FY2024 with a 10-year CAGR of +15.4%.
Declined from $28M to $19M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +32.5%
- 10-Year CAGR
- +15.4%
Key checks
Key Insights
- 5-year CAGR of +32.5%, indicating consistent growth.
- In FY2024, working capital decreased 19.1% year-over-year.
- Peak working capital was recorded in FY2022.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $18.9M | -19.1% |
| FY2023 | $23.3M | -17.2% |
| FY2022 | $28.2M | +244.3% |
| FY2020 | $8.2M | +77.4% |
| FY2019 | $4.6M | +7.9% |
| FY2018 | $4.3M | -30.2% |
| FY2017 | $6.1M | +108.9% |
| FY2016 | $2.9M | -53.5% |
| FY2015 | $6.3M | +39.7% |
| FY2014 | $4.5M | +601.1% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026